[Asia Economy Reporter Geum Bo-ryeong] Mcare ICS announced on the 8th that it has obtained approval from the U.S. Food and Drug Administration (FDA) for its ventilator 'MTV1000'.



Mcare ICS explained, "The expected effect is to assist the breathing of patients with respiratory distress and improve respiratory failure through continuous or intermittent mechanical ventilation. It supplies warmed and humidified high-flow oxygen to patients suffering from hypoxia due to lung disease, increasing functional residual capacity and reducing anatomical dead space, thereby improving pulmonary oxygenation."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing